Tolerability of PLD/Oxaliplatin Regimen in Recurrent Ovarian Cancer Patients With Previous Fragility to Carboplatin/Paclitaxel Treatment

作者：Dalla Palma Maurizia; Lombardi Giuseppe; Donach Martin E; Borgato Lucia; Zustovich Fable; Furini Lara; Nicoletto Maria O^*

来源：American Journal of Clinical Oncology: Cancer Clinical Trials , 2011, 34(3): 305-308.

DOI：10.1097/COC.0b013e3181e1cb22

• ovarian cancer
• myelotoxicity
• carboplatin
• paclitaxel
• pegylated liposomal doxorubicin
• oxaliplatin

Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel.
Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008.
Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m(2), respectively, over 2 day, every 4 weeks.
Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.

• 出版日期2011-6